2019
DOI: 10.1016/j.clinbiochem.2019.09.001
|View full text |Cite
|
Sign up to set email alerts
|

PCSK9 and atherosclerosis burden in the coronary arteries of patients undergoing coronary angiography

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
8
0
1

Year Published

2020
2020
2024
2024

Publication Types

Select...
4
1
1

Relationship

1
5

Authors

Journals

citations
Cited by 9 publications
(9 citation statements)
references
References 48 publications
0
8
0
1
Order By: Relevance
“…The best-known function of PCSK9 is its effect on low density lipoprotein receptor (LDLR), to which it can bind and thereby facilitate its lysosomal degradation. Lately, PCSK9 is the focus of various studies in different clinical contexts as a marker for cardiovascular risks [13][14][15][16][17] independent of other known traditional risk factors and independent of its influence on LDLR. PCSK9 is thought to play an important role in cardiovascular diseases (CVDs) via different mechanisms, either through binding to Epidermal Growth Factor (EGF) domains on receptors or through binding with receptors present in lipid rafts and associated cell membrane micro-domains or by influencing the gene expression and protein response of various factors involved in the development of cardiac complications [18].…”
Section: Introductionmentioning
confidence: 99%
“…The best-known function of PCSK9 is its effect on low density lipoprotein receptor (LDLR), to which it can bind and thereby facilitate its lysosomal degradation. Lately, PCSK9 is the focus of various studies in different clinical contexts as a marker for cardiovascular risks [13][14][15][16][17] independent of other known traditional risk factors and independent of its influence on LDLR. PCSK9 is thought to play an important role in cardiovascular diseases (CVDs) via different mechanisms, either through binding to Epidermal Growth Factor (EGF) domains on receptors or through binding with receptors present in lipid rafts and associated cell membrane micro-domains or by influencing the gene expression and protein response of various factors involved in the development of cardiac complications [18].…”
Section: Introductionmentioning
confidence: 99%
“…Using the SYNTAX score to assess coronary severity is reasonable and meets the current guidelines, such as for use in myocardial infarction [ 19 , 32 ]. Recent studies have also shown that high levels of Pcsk9 can be considered as new and reliable biomarkers for the presence and severity of CHD [ 13 , 23 , 24 ]. Also, the circulating concentration of Pcsk9 increased in the first few hours/days after acute coronary syndrome (ACS) [ 23 , 33 ].…”
Section: Discussionmentioning
confidence: 99%
“…Recent studies have also shown that high levels of Pcsk9 can be considered as new and reliable biomarkers for the presence and severity of CHD [ 13 , 23 , 24 ]. Also, the circulating concentration of Pcsk9 increased in the first few hours/days after acute coronary syndrome (ACS) [ 23 , 33 ]. Serum Pcsk9 levels are related to SYNTAX scores in patients with acute or stable CAD [ 20 23 ].…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations